“Surprise!” was the word of the day yesterday for Acadia (ACAD) stock holders as the company announced shocking news at the end of the day. Acadia (ACAD) announced that the CEO of the company has suddenly decided to retire; and that wasn’t all. Another shocking kick to the groin of investors was the fact that the company is delaying the new drug application for their proposed Parkinson’s disease treatment. As a result of the news, Acadia (ACAD) stocks fell dramatically in after hours trading and continues to fall today. The stock is currently (1:57) down $10.18 per share from yesterday’s close; the stock is trading at $34.52 and the downtrend seems to be continuing.
Outlook – I wouldn’t put a penny into this stock until I heard more details with regard to why the NDA was delayed; readiness just isn’t enough for me. I want to know why they weren’t ready and what they’re doing to fix the problem! Not to mention, there’s still that fishy issue of the CEO retiring suddenly and without reason.
Amarin (AMRN) Stocks Fly High On Analyst Upgrade!
On the positive side of BioTech, we have Amarin (AMRN). Here we have a stock that is experiencing a strong uptrend; and for good reason. This morning, we learned that Andrew Fein, an analyst at HC Wainwright upgraded the stock from “Neutral” to “Buy” and set a target price at a staggering $10. This is the second mainstream analyst upgrade we’ve seen on the stock in under a month! As a result, Amarin (AMRN) stock values are soaring. Currently, 1:03, the stuck is up 25.06% trading at $2.43 per share and climbing.
Outlook – If you’re looking for a BioTech company to invest in, Amarin (AMRN) should be a strong consideration. The company’s stock is up exponentially over the past 30 days. With the average price target among analysts at $5, and many analysts rating it higher, this one’s an easy call!
Cytori (CYTX) Stocks Seem Confused As Investors Anticipate Earnings
Today is a big day for Cytori (CYTX). Today, shortly following the closing bell, Cytori (CYTX) will be releasing their earnings report for the quarter ending December 31st, 2014 as well as their year end results for the entire year of 2014. As we see often the day of an after the bell earnings report, Cytori (CYTX) stocks seem to be stumbling. While the stock is currently (1:11) down more than 3% on the day, the overall sentiment on StockTwits.com with regard to earning expectations seems to be positive.
Outlook – While I’d be hesitant to make any moves before the release of Cytori (CYTX) earnings report, I am very excited to see what happens. In the past, I’ve noticed that investor sentiment on social channels tends to be a good indicator of what will happen from time to time. With that said, I think we’re going to see a positive report and Cytori (CYTX) stocks will be up in after-hours trading.
Neuralstem (CUR) Stocks Are Down In A Big Way Following Shaky ALS Treatment Results
Recently, Neuralstem (CUR) released test results for it’s ALS therapy that is currently in development. The safety results provided were great! Some outlets would even call them “top-line”! Unfortunately however, it seems as though there may be a problem with the release. Officials found that some of the efficacy data provided by Neuralstem (CUR) seems to be a bit shaky; calling the entire therapy development process into question. As a result, the company’s stock has tanked so far today. Current, (1:22) it’s trading at $2.86 per share after falling 23.53% from its closing price yesterday.
Outlook – This one is one to stay away from my friends. Investigators are currently looking into claims made by Neuralstem (CUR). If the investigation turns up any negative information, this thing could fall like a brick!
Genetic Technologies (GENE) Stocks Are Headed Back Up
Last week, Genetic Technologies (GENE) announced that it had raised $18.6 million by issuing new shares. While that sounds great on the outside, what the move really did was dilute the market; driving the price of Genetic Technologies (GENE) stock down. However, it seems as though we’ve reached the bottom of the trend. Currently (1:27), the stock is trading at $4.62 per share after gaining 9.14% so far today.
Outlook – Because we’re fresh off of a downtrend, now is the time to move on this one. The bottom line is that Genetic Technologies (GENE) is a great company that I believe will grow. So, I’m not sure we’re going to see prices this low again for quite some time.
What Do You Think?
What are your opinions of the stocks mentioned here? Let us know in the comments below!